141 related articles for article (PubMed ID: 16858245)
1. Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin.
Hrovatin E; Viel E; Lestuzzi C; Tartuferi L; Zardo F; Brieda M; Dametto E; Piazza R; Antonini-Canterin F; Vaccher E; Meneguzzo N; Nicolosi GL
J Cardiovasc Med (Hagerstown); 2006 Aug; 7(8):637-40. PubMed ID: 16858245
[TBL] [Abstract][Full Text] [Related]
2. Acute coronary syndrome secondary to fluorouracil infusion.
Lu JI; Carhart RL; Graziano SL; Gajra A
J Clin Oncol; 2006 Jun; 24(18):2959-60. PubMed ID: 16782933
[No Abstract] [Full Text] [Related]
3. A case of acute myocardial infarction during 5-fluorouracil infusion.
Canale ML; Camerini A; Stroppa S; Porta RP; Caravelli P; Mariani M; Balbarini A; Ricci S
J Cardiovasc Med (Hagerstown); 2006 Nov; 7(11):835-7. PubMed ID: 17060812
[TBL] [Abstract][Full Text] [Related]
4. [Reversible cardiogenic shock under 5-fluorouracil treatment].
Bakouboula B; Morel O; Douchet MP; Chauvin M
Ann Cardiol Angeiol (Paris); 2005 Aug; 54(4):216-9. PubMed ID: 16104623
[TBL] [Abstract][Full Text] [Related]
5. Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.
Eskilsson J; Albertsson M; Mercke C
Radiother Oncol; 1988 Sep; 13(1):41-6. PubMed ID: 3187073
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil-Induced cardiotoxicity.
Shanmugasundaram S; Bharathithasan R; Elangovan S
Indian Heart J; 2002; 54(1):86-7. PubMed ID: 11999096
[TBL] [Abstract][Full Text] [Related]
7. [The present situation of neoadjuvant therapy for head and neck carcinoma].
Rikimaru F; Tomita K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1535-7. PubMed ID: 17940367
[TBL] [Abstract][Full Text] [Related]
8. Acute heart failure after treatment with 5-fluorouracil.
Georgieva S; Kinova E; Iordanov V; Gudev A; Tzekova V; Velikova M
J BUON; 2007; 12(1):113-6. PubMed ID: 17436411
[TBL] [Abstract][Full Text] [Related]
9. A case of myocardial ischaemia induced by 5-fluorouracil.
Görgülü S; Oğuz E; Zor A; Zor U; Gürdoğan M; Tezel T
Anadolu Kardiyol Derg; 2002 Sep; 2(3):259-61. PubMed ID: 12223336
[No Abstract] [Full Text] [Related]
10. The need for routine monitoring of cardiac function in patients receiving 5-fluorouracil infusion.
Francis N
Clin J Oncol Nurs; 2014 Jun; 18(3):360-2. PubMed ID: 24867118
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of administration with S-1 alone for head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():144-9. PubMed ID: 16897991
[TBL] [Abstract][Full Text] [Related]
12. [Infusor--an aid in cytostatic therapy].
Norum J; Wist E
Tidsskr Nor Laegeforen; 1991 Jun; 111(16):1979-80. PubMed ID: 1866732
[TBL] [Abstract][Full Text] [Related]
13. Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report.
Akpek G; Hartshorn KL
Cancer Chemother Pharmacol; 1999; 43(2):157-61. PubMed ID: 9923822
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC).
Rivera F; Vega-Villegas ME; López-Brea M; Isla D; Mayorga M; Galdós P; Rubio A; Del Valle A; García-Reija F; García-Montesinos B; Rodríguez-Iglesias J; Mayordomo J; Rama J; Saiz-Bustillo R; Sanz-Ortiz J
Cancer Chemother Pharmacol; 2008 Jul; 62(2):253-61. PubMed ID: 17901953
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
16. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.
Lestuzzi C; Vaccher E; Talamini R; Lleshi A; Meneguzzo N; Viel E; Scalone S; Tartuferi L; Buonadonna A; Ejiofor L; Schmoll HJ
Ann Oncol; 2014 May; 25(5):1059-64. PubMed ID: 24558023
[TBL] [Abstract][Full Text] [Related]
17. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.
Rades D; Fehlauer F; Sheikh-Sarraf M; Kazic N; Basic H; Poorter R; Hakim SG; Schild SE; Dunst J
Head Neck; 2008 Feb; 30(2):235-41. PubMed ID: 17657790
[TBL] [Abstract][Full Text] [Related]
19. [Myocardial necrosis and cardiogenic shock with normal coronaries: cardiotoxicity due to 5-FU or catecholamine cardiomyopathy].
Rodríguez Roldán JM; Lara Alvarez MA; López Martínez J; Díaz Abad R; Caballero Campo M; Del Nogal Sáez F
Med Intensiva; 2006 Apr; 30(3):123-4. PubMed ID: 16729482
[No Abstract] [Full Text] [Related]
20. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
Boku N; Ohtsu A; Yoshida S; Shirao K; Shimada Y; Hyodo I; Saito H; Miyata Y;
Jpn J Clin Oncol; 2007 Apr; 37(4):275-81. PubMed ID: 17522103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
